Abstract 9899: Understanding the Venus and Mars Effect: Sex-Based Differences Across a Spectrum of Cardiovascular Biomarkers
It is unknown whether sex-based differences in the prevalence and pathobiology of cardiovascular disease (CVD) can be informed by cardiovascular biomarker profiles. We analyzed sex-based differences in multiple biomarkers associated with CVD that reflect unique biological pathways, adjusting for differences in CVD risk factors and body composition.
Methods: A cross-sectional analysis was performed using data from the Dallas Heart Study, a multi-ethnic probability based cohort study. Participants with existing CVD were excluded. Associations between sex and 26 distinct biomarkers were evaluated using multivariable linear regression adjusting for age, race, traditional CVD risk factors, MRI and DEXA measures of body composition and fat distribution, renal function, insulin resistance, LV mass by MRI, and menopausal status.
Results: The study population included 3557 individuals, mean age 43, 56% women and 52% African American. Significant sex-based differences were seen in multiple categories of biomarkers, including lipids, adipokines, and biomarkers of inflammation, endothelial dysfunction, myocyte injury and stress, and renal dysfunction. In fully adjusted models, women had higher levels of HDL-C and HDL-p, leptin, d-dimer, osteoprotegerin (OPG), and NT-proBNP, and men had higher levels of lipoprotein-associated phospholipase A2 (LP-PLA2), monocyte chemoattractant protein-1 (MCP-1), soluble endothelial cell adhesion molecule (sESAM), symmetric dimethylarginine (SDMA), hs-cTnT, and cystatin C (Table).
Conclusion: Even after accounting for sex-based differences in traditional CVD risk factors, body composition and insulin resistance, important differences in biomarker profiles exist between women and men without CVD in the population. Future studies are needed to characterize whether pathophysiological processes delineated by these biomarkers contribute to sex-based differences in the development and complications of CVD.
Author Disclosures: J. Lew: None. A. Rohatgi: None. D.K. McGuire: None. M. Sanghavi: None. C.R. Ayers: None. M.O. Gore: None. J.D. Berry: None. A. Khera: None. J.A. de Lemos: Consultant/Advisory Board; Modest; Novo Nordisc, St. Jude Medical. Research Grant; Significant; Roche Diagnostics, Abbott Diagnostics.
- © 2015 by American Heart Association, Inc.